Various pharmacological studies have implicated the dopamine D 3 receptor as an interesting therapeutic target in the treatment of different neurological disorders. Because of these putative therapeutic applications, D 3 receptor ligands with diverse intrinsic activities have been an active field of research in recent years. Separation of purely D 3 -mediated drug effects from effects produced by interactions with similar biogenic amine receptors allows to verify the therapeutic impact of D 3 receptors and to reduce possible side-effects caused by "promiscuous" receptor interactions. The requirement to gain control of receptor selectivity and in particular subtype selectivity has been a challenging task in rational drug discovery for quite a few years. In this review, recently developed structural classes of D 3 ligands are discussed, which cover a broad spectrum of intrinsic activities and show interesting selectivities.
Introduction
In more than 15 years of research since the discovery of the D 3 receptor by Sokoloff et al. [1] , enormous progress has been made in improving our understanding of its physiological function and pharmacological impact. Being preferentially located in brain regions which have an impact on emotional and cognitive functions, such as e.g. the nucleus accumbens and the islands of Calleja [2] [3] [4] , the D 3 receptor is capable of affecting behavioral properties, such as locomotor activity, reinforcement and reward. Thus, various pharmacological studies have investigated the D 3 system as an interesting therapeutic target for the treatment of schizophrenia [5, 6] , Parkinson's disease [7] , drug-induced dyskinesia [8] and drug abuse (in particular cocaine addiction) [6, 9] . Moreover, D 3 might be involved in the cortical development during gestation obviously orchestrating neuronal migration and differentiation [10] .
Neuroprotective effects during the induction phase of Parkinson's disease have been reported for D 3 receptor agonists, such as pramipexole (2) . Recently, the selective D 3 partial agonist FAUC 329 (30) has been evaluated in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease [11] . FAUC 329 showed most pronounced neuroprotective effects on dopamine (DA) depletion in the nucleus accumbens. reflecting the preferential abundance of D 3 receptors in this region [12] . Moreover, it has been demonstrated that the D 3 selective partial agonist BP 897 (27) inhibits cocaineseeking behavior caused by the presentation of drug-associated cues, however, in the absence of any intrinsic, primary rewarding effects [9] . While D 3 agonists have already been established as valuable treatment alternatives in PD [13, 14] , the more recently discovered selective D 3 partial agonists and antagonists are currently evaluated for their clinical relevance.
Homology-based difficulty to gain selectivity among D 2 -like receptors
Parallel to gaining a more detailed insight into D 3 receptor pharmacology and to the evaluation of respective treatment opportunities, the available D 3 ligands have undergone a structural evolution: mostly driven by rational drug discovery, small, dopamine-related agonists have evolved into structurally diverse agents with high affinity, selectivity over the closely related biogenic amine receptors and a broad range of intrinsic activities. However, gaining selectivity for D 3 versus the other D 2 -like receptors (in particular D 2 ) has been a challenge in medicinal chemistry for quite a few years. This challenge was predominantly based on a distinct structural homology between the D 2 -like receptors and the absence of direct structural data about the dopaminergic or even any aminergic receptors.
As outlined in Fig. 1 , an elaborate sequence alignment of the D 2 -like wild type receptors [15] , which is largely consistent with previous investigations [16, 17] reveals a moderate overall sequence identity between D 2 and D 4 (∼ 32%) or D 3 and D 4 receptors (∼34%). However, the overall sequence identity for D 2 and D 3 receptors is significantly higher (∼ 50%). Extending the comparison criteria from identity to similarity (as defined by the use of a Gonnet250 similarity matrix [18] ) confirms the trend observed for identity comparison. The similarity scores are: 48% for D 2 
Recent progress in controlling subtype selectivity and intrinsic activity of D 3 ligands
Because of the various putative therapeutic applications, D 3 receptor ligands with diverse intrinsic activities have been an active field of research in recent years. Separation of purely D 3 -mediated drug effects from effects produced by interactions with similar biogenic amine receptors allows to improve the significance of insights into the therapeutic impact of D 3 receptors and to reduce possible side-effects caused by "promiscuous" receptor interactions. Thus, there is the necessity to gain control of receptor selectivity and in particular subtype selectivity, which has been a challenging task in rational drug discovery for quite a few years. In this review, we present some recently developed structural families of D 3 ligands covering a broad spectrum of intrinsic activities and showing interesting selectivities.
Heterocyclic agonists
Similarity replacement of atoms, functions or moieties based on physicochemical or topological aspects has lead to numerous bioisosters of the genuine neurotransmitter dopamine (1). For instance, exchange of the catechol substructure of DA into a heterocyclic aminothiazole moiety and rigidization of the flexible aminoethyl side chain (Scheme 1) has yielded pramipexole (2), which has become a reference D 3 agonist for in vitro and in vivo studies, as well as a standard therapeutic [75] . Only marginal manual improvements were necessary using the alignment editor GeneDoc [76] . A consensus sequence was generated by applying standard criteria from MULTALIGN [77] : uppercase is identity, lowercase is consensus level >0.6, ! is any one of the amino acid groups IV, $ is any one of LM, % is any one of FY, # is any one of NDQEBZ. Residues contributing to this consensus are drawn as white letters on black background, when strictly conserved throughout all 3 sequences, or shaded in gray when conserved in terms of any other MULTALIGN rules. The transmembrane domains TM1 to TM7 and the adjacent helix H8 are denoted above the sequences. The cylinders are color-coded corresponding to the D 3 receptor model depicted above the sequence alignment. Filled areas of the cylinder reflect parts of the sequence, where all 3 receptors show helical structures in a recent comparative modeling study [15] . Cylinder areas without filling represent parts of the sequence that are found to be helical only in some of the dopamine receptor models. Both sequence numbers as well as residue numbers according to the Ballesteros and Weinstein numbering scheme [78] are given. The phylogenetic tree illustrates sequence homologies among dopamine receptors. agent for Parkinson's Disease. Being a valuable alternative to the "gold standard" L-Dopa, pramipexole is frequently used as an adjunct therapy to reduce L-Dopa doses in later stages of PD or, particularly, in early-onset patients to delay the begin of L-Dopa therapy. The D 3 affinity of 2 is consistently high (K i = 0.5 to 8.5 nM), but D 3 :D 2 -selectivity varies from weak (∼ 8-fold) to strong (∼193-fold) [19] [20] [21] being largely depended on the assay conditions. Measured in mitogenesis assay, the intrinsic activity of pramipexole is ∼ 100% at D 2 and ∼ 80% at D 3 receptors as compared to the effect of quinpirole [21] , which is frequently used as a reference for full agonism [22] in this functional assay. The ∼ 8-fold functional selectivity for D 3 (EC 50 = 0.29 nM) versus D 2 receptors (EC 50 = 2.4 nM) is in agreement with previous studies that reported a ∼ 15-fold selectivity [19] .
Rationalizing that a pyrrole moiety can act as a catechol bioisostere as well, a novel series of ligands was constructed by diversifying the position of the nitrogen throughout the fivemembered aromatic ring. Thus, various regioisomeric azabicyclo[4.3.0]nonanes (Table 1 , Scheme 2) were generated including 6-and 7-aminotetrahydroindolizines [23] [24] [25] , 5-aminotetrahydroisoindoles and 5-and 6-aminotetrahydroindoles [26] . The highest affinity for D 3 among the unsubstituted derivatives (R = H) is found for the 1-aza (K i = 38 nM for (S)-6) and 2-aza analogs (K i = 33 nM for (S)-5), showing both considerable eutomer:distomer differences to their (R)-enantiomers [26] . In contrast to (S)-5, a high-affinity binding site for (S)-6 can only be detected at the D 3 , but not at the D 2 or D 4 receptor subtypes. Comparing the N-methyl (8) or N-formyl (9) with the unsubstituted (S)-enantiomer of the 1-aza-series (6) indicates that these substitutions hardly affect D 3 receptor binding. It is notable that (R)-9 exhibits similar affinity for the D 3 receptor as (S)-9 giving an eudismic (eutomer:distomer) ratio of ∼ 0.9 and even higher affinities than (S)-9 for the D 2 and D 4 subtypes. Despite the weak binding of the unsubstituted 7a-aza derivative (7) to D 3 receptors, introduction of a formyl (10) or cyano substituent (11) enhances the affinities substantially (K i = 5.3 nM for (S)-10 also known as FAUC 54 and K i = 7.2 nM (S)-11). Again, (S)-10 and (S)-11 are clearly the eutomers exhibiting substantial eudismic ratios of 0.0029 and 0.0026, respectively. The ∼10-fold preference of FAUC 54 for D 3 over D 2 receptors increases by a factor of ∼ 26 for (S)-11, while the ∼6-fold 50 [nM] determined in rat brain striatum [23] . f D 1 binding determined with porcine D 1 receptors [26] . g K i values of the high and low affinity binding state of the receptor, when analysis of the binding data resulted in a biphasic dose-response curve. h [24] . i Hübner and Gmeiner, unpublished results. j [25] . k [27] .
preference over D 4 is maintained. In mitogenesis assay [25] , both are full agonists at D 2 receptors, whereas only FAUC 54 shows near full agonism at D 3 (89% relative to quinpirole) and (S)-11 is a partial agonist (59%). The potencies of these ligands (EC 50 = 2.4 nM for (S)-11 and EC 50 = 1.1 nM for FAUC 54) are comparable to quinpirole (EC 50 = 2.6 nM) in this functional assay. At D 4 receptors, FAUC 54 has relatively strong partial agonistic properties (67%), however, a weak potency (4200 nM) and (S)-11 is a pure antagonist.
As a very recent extension of this series of ligands, the aminotetrahydropyrazolo[1,5-a]pyridine 12 was reported [27] , bearing nitrogens in positions 1 and 7a. In this structure, the hydrogen-bond accepting formyl (10) 
Non-aromatic agonists
For the ligands presented in the previous section, the close relation to the natural ligand DA is still easily visible due to containing an aromatic system at a set distance from a protonatable amine. For quite a long time aromatic or heteroaromatic substructures have been regarded as an essential pharmacophore requirement. However, recently several types of non-aromatic, but conjugated π-systems proved to be able to mimic the catechol nucleus of DA. This appears to be even more remarkable, as most of the potent derivatives are lacking any heteroatomic functions, which could putatively substitute for the polar hydroxyl functions of DA. While polar hydroxyls of their equivalents are expected to be involved in receptor binding [28] [29] [30] , increasing evidence suggests that optimized hydrophobic effects can compensate for the attractive forces resulting from hydrogen bonds (reviewed by [31] ).
In the class of conformationally restrained enynes (Scheme 3), the methyl- (14) and trimethylsilyl-substituted (16) acetylene derivatives exhibit modest D 3 binding (Table 2) , while its unsubstituted analog (13 also known as FAUC 73) has low nanomolar D 3 affinity (5.2 nM) and ∼52-fold preference for D 3 over D 2 receptors [32, 33] . In contrast to these favorable properties of FAUC 73, several other members of this structural class, such as the hydroxymethyl-substituted (15) or the phenyl-substituted acetylenes (17) , the nitrile analog (18) and the whole class of enediynes (19) (20) (21) are inactive at the D 2 -like receptors. Interestingly, none of the ligands with putative hydrogen-bonding properties (e.g. 15 or 18) shows any significant receptor binding.
Exchanging the acetylene in 13 by a vinyl function produced the diene FAUC 206 (22) , which exhibits notable D 3 affinity (5.6 nM) and preference over D 2 (41-fold) . Additionally, FAUC 206 displays improved preference of 64-fold for D 3 over D 4 receptors [33] . Experimental and computational investigations suggest that the s-trans-isomer should be considerably favored. The high affinity of FAUC 206 for D 3 implies that specific hydrogen bond-like interactions of the acetylene proton in Scheme 2. FAUC 73 are of no significance in the anticipated receptorbinding mode of these ligands. Subsequent structure activity relationship studies focusing on the enlargement of the π-electronic system, have led to the introduction of a further triple bond yielding conjugated (aza)endiynes [34] . In addition, a vinyl substituent was alternatively introduced giving a structure of the dienyne type (24) [35] . D 3 affinity is improved by the different substituents in the order: cyano (K i = 26 nM for 23) < vinyl (K i = 9.1 nM for 24) < ethynyl (K i = 3.2 nM for 25). In fact, the cis-hexendiyne functionality of FAUC 88 (25) is superior to the butenyne moiety of the lead compound FAUC 73 (13) making it the most potent non-aromatic dopamine receptor ligand yet investigated (Table 2) . From a comparison of the molecular electrostatic potentials (Fig. 2) , it becomes obvious that the extended conjugated π-system of FAUC 88 is able to mimic efficiently the molecular electrostatic potential (MEP) of the α-rotamer of dopamine. The high affinities and potencies of compounds presented in this section indicate that aromatic or heteroaromatic systems, although being commonly present in DA agonists, appear to be not essential for molecular recognition or intrinsic activity at the D 3 receptor. Thus, this uncommon ("fancy") bioisosteric replacement of the aromatic by conjugated, but non-aromatic π-systems has proven to be a powerful strategy for the generation of preferential D 3 agonists and could be further exploited for probing the nature of ligand-receptor complexation between π-systems.
4-Phenylpiperazines and analogs with partial agonistic and antagonistic properties
During the last decade, 4-phenylpiperazine has been recognized as a "privileged structure" for biogenic amine receptors. In particular with respect to the application as potent and selective D 3 ligands, the class of 4-phenylpiperazines and its close derivatives have become quite popular. Basically, most of these ligands comprise the following structural features (Scheme 4): An aromatic or heteroaromatic carboxamide (π 1 ) that is connected through a conformationally flexible or (partly) rigidized alkyl-spacer of variable length (spacer) to a piperazine bearing an aromatic or heteroaromatic moiety in position 4 (π 2 ). Across different laboratories diverse in vitro binding affinities and functional potencies have been reported involving some ligands cited in this section. These differences appear to concern predominantly the measurement of D 2 receptor affinities, whereas D 3 affinities are found to be rather consistent. However, D 3 :D 2 selectivity ratios are of course affected. Possible underlying reasons for these discrepancies have been recently discussed [36] .
Modifications of the π 1 moiety
The 2-methoxyphenylpiperazines GR 103691 (26) and BP 897 (27) , as well as the 2,3-dichlorophenylpiperazine NGB 2904 (28) can be regarded as early lead structures of this family of ligands (Scheme 5). The 4′-acetyl-biphenyl-4-carboxamide GR 103691 shows subnanomolar D 3 affinity (0.32 nM) and ∼ 130-fold selectivity for D 3 versus D 2 receptors [37] . Although the selectivities against the other DA receptors subtypes are substantial (e.g. ∼ 1300-fold over D 1 ), distinct affinities for 5-HT 1A (K i = 3.2 nM) and α 1 receptors (K i = 13 nM) have been reported. However, replacement of the 4′-acetyl with a 4′-methylsulphone or a 4′-amino group improves the D 3 :5-HT 1A selectivity.
Variation of the arylcarbamide moiety yielded the 9H-fluoren-3-carboxamide 28 (NGB 2904), a tricyclic D 3 receptor antagonist [38] . High D 3 affinity (K i = 1.4 nM), a > 160-fold selectivity for D 3 versus all other DA receptor subtypes and potent antagonism in mitogenesis assays (EC 50 = 5.0 nM) has been reported for 28. More recently, the 9H-fluorene-9-carboxamide 29, a less linear regioisomer of 28, has been synthesized, but showed only a moderate and nonselective binding profile (K i = 19 nM at D 3 and K i = 10 nM at D 2 ) [39] .
Particular interest in this ligand family has been sparked by the discovery that the naphthamide derivative BP 897 (27) can reduce cocaine-seeking behavior in rats, while it does not produce reinforcement on its own [9, 40] . BP 897 is a high affinity D 3 receptor ligand (K i = 0.92 nM) with proper selectivity (∼66-fold) over D 2 receptors, but also moderate affinity for 5-HT 1A (84 nM), α 1 (60 nM) and α 2 receptors (83 nM). The affinities for 5-HT 7 , histamine, muscarinic and opiate receptors have been found to be very low or even negligible. Other investigators [41] report its D 3 affinity and selectivity over D 2 to be slightly weaker (1.6 nM; ∼ 38-fold). BP 897 is a partial agonist at the human D 3 receptor measured by the decrease in forskolin-induced cAMP synthesis (max. effect relative to quinpirole = 59% and EC 50 = 1 nM) or by stimulating mitogenesis (max. effect = 55% and EC 50 = 3 nM) [9, 42] . However, in more recent studies BP 897 has been characterized as an antagonist, as it potently (pK b = 9.43) inhibits the acidification response of quinpirole, while alone it has no effect [41] . Moreover, BP 897 does not modify the basal levels of [ 35 S]GTPγS, whereas the ligand dosedependently (IC 50 = 0.31 nM) inhibits the effects of DA [43] . Mitogenesis as well as microphysiometry experiments indicate that BP 897 is an antagonist at D 2 receptors [9, 41] .
Based on the lead structures of BP 897 and NGB 2904, more selective D 3 partial agonists and antagonist have been discovered. As the pyrazolo-[1,5-a]pyridine moiety acts as a heterocyclic bioisostere of the naphthamide substructure of BP 897, it provides an excellent opportunity for the fine-tuning of selectivity and intrinsic efficacy [44] . Exploiting all possible attachment points of the pyrazolo- Two other very interesting members of these series of heteroaromatic bioisosteres of BP 897 and NGB 2904, the indol-2-carboxamide (38) and 6-cyano-indol-2-carboxamide (39), have been disclosed in the patent literature [49] .
Structure-activity studies starting from D 4 selective ligands have also yielded 32, 34 and 38, which all have high D 3 affinity and selectivity over other related receptors [45] . Variation of the spacer length again produced the rank order: butyl > pentyl > propyl > ethyl, which is in agreement with previous results regarding the optimal spacer length. Variations of the π 2 moiety for the 3-methoxyphenylcarboxamides revealed that the replacement of the commonly used 2,3-dichlorophenyl by a 2,3-dimethylphenyl group (40) maintains D 3 affinity and increases selectivity to at least 300-fold over D 4 , 5-HT 1A and α 1 receptors. However, the selectivity over D 2 receptors is attenuated from 5200-fold for the 2,3-dichlorophenyl to 450-fold for the 2,3-dimethylphenyl derivative. Other methoxy-substituted compounds obtained by variation of π 1 are the 1-methoxy-2-naphthamide (41) and the 7-methoxybenzo[b] furan-2-carboxamide analog (42) , which exhibit both subnanomolar D 3 affinities (K i = 0.60 nM for 41 and K i = 0.13 nM for 42) and substantial selectivities over D 2 , D 4 , 5-HT 1A and α 1 (> 950-fold for 41 and >840-fold for 42). It should be noted that in this preceding study dopamine receptor subtypes from different species were compared (human D 2 , rat D 3 , and human D 4.4 ) and, thus, it has been argued that selectivities might be influenced by species differences [36] . 41 and 42 have been recently evaluated as [ 11 C]-labeled PET ligands [50] . A further series of heteroaromatic BP 897/NGB 2904 bioisosteres has been generated, yielding compounds, such as 43-45 [51] . The 2-indolcarboxamide 43 is closely related to 38, except that the 2,4-dichlorophenyl replaces the 2,3-dichlorophenyl. The 5-chloro-indole-2-carboxamide derivative 44 shows almost the same binding profile as 43, but 44 acts as a partial agonist in [ 35 S]GTPγS assays, whereas 43 is an antagonist. For 43 a partial reduction of cocaine-seeking behavior has been observed in rats, while 44 fails to show any effect in this animal model. Interestingly, the 1,2,3,4-tetrahydropyrazino [1,2-a]indole-1(2H)-one 45 retains high affinity for D 3 (0.87 nM), even though it lacks both the indole-NH and the carboxamide-NH hydrogen bonding capacity. However, the selectivity for D 3 over other receptors was reduced for 45 (∼52-fold over D 2 , ∼ 38-fold over α 1 , and ∼ 5.6-fold over 5-HT 1A ). Hence, the hydrogen bond donor function of the carboxamides may have an impact on subtype selectivity, but certainly not on D 3 receptor recognition.
A new series of o-methoxyphenylpiperazine analogs has been developed by replacing the naphthamide in BP 897 with (E)-cinnamide derivatives [52] . The iodo-substituted analogs 47-49 possess increased selectivity for D 3 over D 2 receptors in comparison to the unsubstituted (E)-cinnamide 46, while they maintain high D 3 affinity. The selectivity increases from 42-fold (46) to 84-fold for the 2-iodo-cinnamide (47), 130-fold for the 3-iodo-cinnamide (48) and 150-fold for the 4-iodo-cinnamide (49) . The 4-iodo-cinnamide (49 also known as ST 280) exhibits the best pharmacological profile in this series and thus has been ascribed to be a promising radioligand candidate. Exploiting the benzamide structure and some heteroaromatic bioisosteres in further structural modifications of the π 1 moiety has led to the 4-dimethylaminobenzamide derivative 50, the 4-methylsulfanylbenzamide 51 and the 5-bromo-2,3-dimethoxybenzamide 52 [47, 53] . All three ligands feature high affinity binding to D 3 receptors (K i = 0.8 nM for 50, K i = 0.6 nM for 51, and K i = 2.1 nM for 52) and a moderate preference for D 3 versus D 2 receptors (43-fold for 50, 53-fold for 51, and 28-fold for 52). While 52 has been reported to bind with appreciable affinity at σ 1 (809 nM) and σ 2 receptors (75 nM), 50 and 51 both show considerable affinity for 5-HT 1A receptors (K i = 6.0 nM for 50 and K i = 1.5 nM for 51). Measuring the inhibition of forskolininduced adenylyl cyclase activity, 50 has been determined to be a weak partial agonist (21% of the maximal effect).
As the development of potent and selective positron emission tomography (PET) tracers for D 3 receptors has been deemed an important step to investigate the role of this receptor subtype in the pathophysiology of numerous diseases, a series of [ 18 F]-labeled PET tracers has been synthesized taking advantage of 4-bromophenyl carboxamide as a lead structure [54] . When combined with 2-methoxyphenyl as π 2 moiety, the resulting 4-fluorophenyl carboxamide 53 and 6-fluoropyridin-3-yl carboxamide 55 exhibit nanomolar D 3 affinities (4.3 nM for 53 and 14 nM for 55), while in combination with 2,3-dichlorophenyl the D 3 affinities are further increased (0.53 nM for the 4-fluorophenyl carboxamide 54 and 1.1 nM for the 6-fluoropyridin-3-yl carboxamide 56). All of these ligands share a moderate preference for D 3 over D 2 receptors (11 to 32-fold), whereas the 2,3-dichloro substitution pattern clearly enhances the selectivity for D 3 over D 4 (83-fold for 54 and 91-fold for 56), 5-HT 1A (110-fold for 54 and 25-fold for 56) and α 1 (32-fold for 54 and 15-fold for 56) at least by a factor of 10 as compared to the 2-methoxy derivatives 53 and 55, respectively. For the 6-fluoropyridin-3-yl carboxamides 55 and 56 a significantly higher radiochemical yield (RCY) of >80% has been reported. Exchange of the carboxamide in 53 and 54 in the respective sulfonamides 57 and 58 gives a most interesting insight into the nature of ligand receptor recognition. Upon this modification the D 3 affinity is substantially impaired (49-fold for 57 and 30-fold for 58), while the D 2 affinity is approximately preserved and the D 4 affinity is even slightly improved. This suggests that an extended planar π system might contribute more to efficient D 3 receptor binding, than hydrogen bonding capabilities of the carboxamide or sulfonamide can do.
Modifications of the π 2 moiety
As a balanced lipophilicity is know to be crucial for drug bioavailability and permeation of the blood-brain barrier, tuning of the calculated logP (clogP) by evaluating different π 2 moieties has been performed in a recent study aiming to identify potential PET radioligands [55] . Trying to increase the chemical diversity in D 3 ligand design, a computational 3D database screening strategy has helped to identify the hexahydropyrazinoquinoline as a rigidized replacement of the phenylpiperazine moiety [17] [56] . Based on the hypothesis that introduction of a methoxy function attached to positions 7 to 10 of the hexahydropyrazinoquinoline core might be able to form hydrogen bonds toward the conserved serine residues in TM5, respective structural variations of 66 have been performed (Scheme 8). Methoxy functions in position 7 or 10 are able to increase both D 3 affinity, as well as selectivity over D 2 receptors, whereas a methoxy substituent in position 9 impairs both affinity and selectivity. Interestingly, when introducing a methoxy group in position 8, the D 3 affinity is considerably decreased, however, the selectivity over D 2 receptors increases significantly indicating that this modification is far more detrimental for D 2 than for D 3 receptor binding.
Going beyond modifications of π 2 , in a recent study the entire phenylpiperazine has been structurally reduced to the essential requirements of a basic nitrogen connected to an aryl group through an aliphatic linker [57] . Higher degrees of rigidity with varying geometry and hydrogen-bonding capabilities were introduced to diversify this phenylalkylamine scaffold. Despite the fact that it has turned out to be not trivial to find a valid bioisostere for the "privileged structure" phenylpiperazine, two scaffolds have been retrieved in this study: the 2-aminoindan and the 1,2,3,4-tetrahydroisoquinoline (Scheme 9). Combining (E)- [8] . ST 198 has been employed in pharmacological studies investigating dopamine autoreceptors in guinea pigs [58] and exhibits attenuation of L-DOPA-induced dyskinesias in monkeys simultaneous with a deterioration of PD-like symptoms and ablation of locomotor activity below the 'on-time' threshold [8] . Iodination of the para-position of the (E)-cinnamide leading to the (E)-3-(4-iodophenyl)acryl-derivative 72 (ST 283) preserves D 3 binding (12 nM) and doubles its selectivity over D 2 receptors (130-fold). ST 283 has been suggested as a useful D 3 -selective radioligand with putative applicability in single-photon emission computed tomography (SPECT) [57] .
Further extensions of the π 1 moiety
Using a ligand-based virtual screening approach, a ligand (73) comprising a shortened π 1 moiety attached to a 3-chlorophenylpiperazine though a n-butylene spacer was identified [59] . In the 3-oxo-2,3-dihydro-benzo [1, 4] oxazin-4-yl (π 1 ) moiety the aromatic ring is shifted to a lateral position and thus should fail to mimic the interactions of the "regular" (hetero-) aromatic substructure (Scheme 10). However, 73 was demonstrated to retain still a D 3 affinity of 40 nM, as well as a 14-fold preference over D 2 . Therefore, 73 may indeed be a novel lead structure representing a distinct mode of interaction.
In contrast to this "truncation" of the π 1 moiety in 73, considerably more efforts have been made to extend it similar to Scheme 9.
Scheme 10.
the enlarged aromatic systems of GR 103691 (26) or NGB 2904 (28) . Employing a parallel derivatization method the 4-phenoxyphenyl derivative 74 and the 1-cyclohexylmethyl derivative 75 have been obtained [60] . Both 74 and 75 exhibit low nanomolar affinity to D 3 receptors (1.6 nM and 2.0 nM, respectively) and a good selectivity over D 2 receptors (140-fold and 160-fold, respectively). Taking advantage of a click chemistry based BAL linker, a solid phase supported parallel synthesis of a focused library of arylcarboxamides has led to the biphenyl-4-carboxamide 76, which is attached to a 2-chlorophenylpiperazine moiety by a tetramethylene spacer [61] . This compound has subnanomolar affinity for D 3 Employing click chemistry-based 1,3-dipolar cycloaddition to synthesize a focused library of N-benzyl-1,2,3-triazole carboxamides has yielded a series of superior picomolar α 1 ligands. Some of these show also high D 3 affinity. For instance the 1-(2-bromo)benzyl-5-propyl-1,2,3-triazole-4-carboxamide 85 binds with low nanomolar affinity to D 3 receptors (K i =3.5 nM) and also with subnanomolar affinity (K i =0.15 nM) to α 1 receptors. This very high α 1 affinity appears to be related to the presence of a 2-methoxyphenylpiperazine moiety, as this picomolar affinity is strongly impaired when changing to a 2,3-dichlorophenylpiperazine. The 1-benzyl-5-propyl-1,2,3-triazole-4-carboxamide derivative 86 for example bears a 2,3-dichloro substitution pattern at the phenylpiperazine and binds with only 5.5 nM to α 1 , while it preserves a low nanomolar binding to D 3 receptors (K i = 2.4 nM).
Aiming to develop new atypical antipsychotics, RGH-1756 (87) has emerged from a series of 2-methoxyphenylpiperazines [62, 63] . Although it is rather uncommon in D 3 receptor ligands, the extended π 1 moiety consisting of a 4-(6-imidazo [2,1-b] thiazolyl)phenyl partial structure is attached to the butylene spacer by an ether group instead of an amide, thus enlarging the flexible spacer and shortening the conjugated π 1 -system on this side. However, despite of the missing carboxamide the linear extension of the π 1 -system to the other side yields a subnanomolar D 3 ligand (K i = 0.12 nM) with high affinity at 5-HT 1A (K i = 0.96 nM) and α 2C receptors (K i = 4.0 nM) and a selectivity of at least 91-fold over α 2A , D 2L , 5-HT 7 , D 2S , D 5 and D 1 receptors [64] . In GTPγS binding assay 87 inhibits the stimulatory effect of dopamine at human D 3 receptors with nanomolar potency (IC 50 = 8.5 nM) [65] . RGH-1756 has been radiolabeled using [ 11 C]methyl triflate [66] and applied to cynomolgus monkeys for PET imaging of the monkey brain [64] . In a recent study on spatial learning performance of rats in a water labyrinth test, RGH-1756 together with other D 3 antagonists improved FG7142-induced learning deficits and scopolamine-induced amnesia [67] . Thus, it has been concluded that the cognition-enhancing effect of D 3 antagonists may be beneficial in the treatment of cognitive dysfunction associated with several psychiatric disorders.
3-Dimensional extensions of the π 1 moiety
Proceeding beyond these two dimensional variations, the thin, "single-layer" π 1 system has very recently been extended to the third dimension by introducing metallocene carboxamides (Scheme 11) [49, 68] . As these bilayered aromatic systems are sterically quite demanding (Fig. 3) As an even more structurally challenging three-dimensional extension of the π 1 system, a series of [2.2] paracyclophanecarboxamide derivatives (92-94) has been synthesized [69] . To investigate the structural effects of the planar chirality of [2.2] paracyclophane, the pure enantiomers (R)-92 (FAUC 418) and (S)-92 have been prepared and tested. Interestingly, the structural difference caused by this planar chirality leads to an eudismic ratio of more than 15 (K i = 3.0 nM for (S)-92 and K i = 0.19 nM for (R)-92). To evaluate the sensitivity of the binding profiles toward the substitution pattern of the phenyl substituent, the 2,3-dichloro, 3-chloro-2-methoxy, and 2,3-difluoro analogs 93, 94, and 95, respectively, have been synthesized. In contrast to the metallocenes 88-91, D 3 receptor binding considerably decreases for all GPCRs when displacing the 2-methoxy group (K i = 3.6 nM for 93 and 1.9 nM for 95). The structural hybrid 94 bearing an ortho positioned methoxy group and a chloro atom in meta position displays an interesting binding pattern with both high D 3 affinity (K i = 0.46 nM) and considerable selectivity over the potential anti-target α 1 (K i = 80 nM). In mitogenesis assay, all paracyclophane derivatives 92-95 revealed an approximately neutral antagonism at the D 3 receptor [69] . This finding appears to be rather surprising, as it is complementary to the group of metallocenes 88-91, where all ligands had partial agonist properties, and differs from the group of monolayered dopaminergics such as BP 897, FAUC 346 and 365, where the intrinsic activity strongly depends on the nature of both the π 1 system and the phenyl substituents.
Further extension of the π 1 moiety was performed though creation of a "chimera" of the benzofuranylcarboxamide 31 and the paracyclophanecarboxamide FAUC 418 (92) resulting in the 1(4,7)benzofurano-4(1,4)benzenehexaphanyl-1 2 -carboxamide 96 [69] . This shift of the bilayered paracyclophane to a more distal position results in a 15-and 84-fold decrease of D 3 affinity as compared to 31 and FAUC 418, respectively. Consequently, 96 points out the limitations of enlarging π 1 .
Rigidization of the spacer
In addition to the modifications already presented concerning the structure of the π 1 or π 2 moieties and the length of the spacer connecting π 1 and π 2 , another strategy towards establishing novel D 3 ligands is the introduction of rigid partial structures into the highly flexible alkyl spacer (Scheme 12). Based on previous studies indicating that the introduction of a cyclohexylethyl spacer was capable of inducing high D 3 affinity [70] , the butylene chain of the 8-methoxy-substituted 66 has been replaced by this rigidized trans-cyclohexylethyl spacer and its piperidine analog. This has been combined with the Scheme 12. discrimination of the enantiomerically pure hexahydropyrazinoquinolines. The (R)-enantiomer (99 and 100) turns out to be slightly superior to the (S)-enantiomer (97 and 98) for both rigidized spacers, however, the corresponding eudismic ratio is just < 2. Using a trans-cyclohexyl-ethyl spacer yields good D 3 affinity (K i = 10 nM for 98 and 4.7 nM for 100) and high selectivity versus D 2 receptors (> 1000-fold for 98 and >1800-fold for 100). Exchange of the trans-cyclohexyl into a piperidine causes a severe loss of D 3 affinity (K i = 7200 nM for 97 and 4600 nM for 99) and D 2 :D 3 selectivity (> 3.5. for 97 and >11 for 99). In order to achieve a more suitable lipophilicity, heteroaromatic derivatives of the racemate of 98/100 have been prepared (Scheme 13) [71] . "Placement" of an aza atom in different positions of the naphthyl moiety yields a number of quinolinyl and isoquinolinyl carboxamides. Only the quinoline-6-carboxamide shows D 3 binding (K i = 9.7 nM) and selectivity over D 2 receptors (460-fold) similar to the naphthyl lead structure.
Other rigid structural elements, such as an o-, m-or pxylenylene spacer (101-103) or a cis-octahydropentalen-2,5-diyl spacer (104) integrated into the BP 897 scaffold [52] result in low to moderate affinities only. This clearly demonstrates that these spacers are hardly able to rigidize the bioactive conformation of BP 897. However, an interesting rank order is found for the D 3 binding of the ligands 101-104. While the o-xylenylene spacer has the most deleterious effect (750 nM), the m-xylenylene is significantly better (100 nM) and the pxylenylene is the best of these three spacers (K i = 40 nM). Thus, the most linear structural element is favored over the more bent elements. Further supporting this observation, also the similarly extended octahydropentalene spacer is found to have comparable D 3 affinity (37 nM).
Introduction of a double or a triple bond into the butylene spacer produces the trans-butenylene derivative 105, the cisbutenylene derivative 106 and the butynylene derivative 107 [72] . While 107 shows a strong decrease in D 3 affinity (390 nM), both 105 and 106 have nanomolar D 3 affinities (1.3 nM and 4.9 nM). Combining the trans-butenylene spacer with established π 1 and π 2 moieties generates partly rigidized structures with considerable D 3 affinities [46] . Both, the 4-pyridin-2-yl-benzamide derivative 108 and the 2-benzothiophene carboxamide derivative 109, retain affinities at D 3 receptors (K i = 0.70 nM for 108 and 1.1 nM for 109) which almost match the affinities of their butylene analogs (K i = 0.50 nM for 77 and for FAUC 365). 
Conclusion
Careful affinity, selectivity and potency "tuning" has resulted in the development of a variety of agonists, partial agonist, and neutral antagonists selective for the dopamine D 3 receptor. Thus, strong D 3 affinities and potencies, considerable selectivities over the other dopamine receptor subtypes, as well as adjusted intrinsic activities have been achieved up to date. Selectivity profiles towards other biogenic GPCRs and pharmacokinetic properties such as bioavailability, blood-brain distribution or drug clearance may represent further dimensions of ligand optimization.
With such a broad variety of ligands available, elucidation of the therapeutic impact of D 3 receptors will most likely further proceed during the forthcoming years. However, the successful treatment of multifactorial CNS diseases might require drugs with balanced receptor binding and efficacy profiles recognizing more than one molecular target. Thus, a paradigm shift from "magic bullets", which are aimed with optimizing selectivity at a single target, towards "magic shotguns" that interact with an optimized spectrum of several targets may be necessary [73] .
Further challenges in D 3 drug discovery may be to find ligands that are able to discriminate between different functional states of the D 3 receptor, which appears to relate to the ability of these receptors to couple to different G proteins. Moreover, there is strong evidence for the ability of rhodopsin-like (type I) G-protein coupled receptors to form homo-or heterodimers (or even higher order oligomers) [74] . In the near future, it may be possible for ligands to distinguish between these higher order oligomerization states of the receptor, which may have an impact on their clinical utility in the treatment of specific central nervous systems diseases.
